Vertex Pharmaceuticals Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Vertex Pharmaceuticals Inc 公司

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

Vertex Pharmaceuticals Inc簡介



公司代碼VRTX

公司名稱Vertex Pharmaceuticals Inc

上市日期Jul 24, 1991

CEOKewalramani (Reshma)

員工數量6100

證券類型Ordinary Share

年結日Jul 24

公司地址50 Northern Avenue

城市BOSTON

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編02210

電話16173416393

網址https://www.vrtx.com/

公司代碼VRTX

上市日期Jul 24, 1991

CEOKewalramani (Reshma)

Vertex Pharmaceuticals Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

90.67K

+38857.00%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+5000.00%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

44.00K

+11333.00%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

33.48K

+9012.00%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

33.05K

+7249.00%

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

24.37K

+9068.00%

Mr. Duncan Mckechnie

Executive Vice President, Chief Commercial Officer

22.93K

+6800.00%

Mr. Lloyd A. Carney

Independent Director

6.32K

-800.00%

Dr. Sangeeta N. Bhatia, M.D., Ph.D.

Independent Director

4.57K

-266.00%

Ms. Jennifer J. Schneider

Independent Director

1.72K

+796.00%

名稱

名稱/職務

職務

持股

持股變動

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

90.67K

+38857.00%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+5000.00%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

44.00K

+11333.00%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

33.48K

+9012.00%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

33.05K

+7249.00%

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

24.37K

+9068.00%

收入明細

單位: USD更新時間: 1月6日週二

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

TRIKAFTA

2.65B

86.26%

ALYFTREK

247.00M

8.03%

Other CF products

175.80M

5.71%

地區USD

名稱

營收

佔比

United States

1.98B

64.24%

Europe

836.90M

27.20%

Other

263.20M

8.56%

業務

地區

業務USD

名稱

營收

佔比

TRIKAFTA

2.65B

86.26%

ALYFTREK

247.00M

8.03%

Other CF products

175.80M

5.71%

股東統計

更新時間: 11月15日週六

持股股東

股東類型

持股股東

佔比

Capital World Investors

10.21%

The Vanguard Group, Inc.

9.45%

Capital Research Global Investors

6.52%

BlackRock Institutional Trust Company, N.A.

5.70%

State Street Investment Management (US)

4.57%

其他

63.53%

持股股東

佔比

Capital World Investors

10.21%

The Vanguard Group, Inc.

9.45%

Capital Research Global Investors

6.52%

BlackRock Institutional Trust Company, N.A.

5.70%

State Street Investment Management (US)

4.57%

其他

63.53%

股東類型

持股股東

佔比

Investment Advisor

60.43%

Investment Advisor/Hedge Fund

27.86%

Research Firm

2.35%

Pension Fund

2.35%

Bank and Trust

2.10%

Sovereign Wealth Fund

1.50%

Hedge Fund

1.14%

Individual Investor

0.19%

Insurance Company

0.06%

其他

2.00%

機構持股



更新時間: 1月1日週四

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

2986

248.55M

97.96%

-4.86M

2025Q3

2933

249.27M

98.24%

-2.14M

2025Q2

2933

252.71M

98.56%

+2.47M

2025Q1

2977

252.24M

98.22%

-39.54K

2024Q4

2877

248.76M

96.87%

-2.25M

2024Q3

2786

247.87M

96.18%

-4.19M

2024Q2

2747

248.36M

96.27%

-4.14M

2024Q1

2680

247.63M

95.87%

-4.48M

2023Q4

2608

247.92M

96.20%

-4.51M

2023Q3

2477

248.64M

96.45%

-6.19M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Capital World Investors

25.91M

10.21%

-2.82M

-9.82%

Sep 30, 2025

The Vanguard Group, Inc.

24.10M

9.5%

+240.67K

+1.01%

Sep 30, 2025

Capital Research Global Investors

16.55M

6.52%

+444.99K

+2.76%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

14.47M

5.7%

+317.50K

+2.24%

Sep 30, 2025

State Street Investment Management (US)

11.61M

4.57%

-169.23K

-1.44%

Sep 30, 2025

Geode Capital Management, L.L.C.

5.97M

2.35%

+45.00K

+0.76%

Sep 30, 2025

Invesco Capital Management (QQQ Trust)

5.69M

2.24%

+318.09K

+5.92%

Dec 31, 2025

Wellington Management Company, LLP

4.77M

1.88%

-41.34K

-0.86%

Sep 30, 2025

Capital International Investors

4.69M

1.85%

+2.05M

+77.89%

Sep 30, 2025

AllianceBernstein L.P.

4.52M

1.78%

+144.27K

+3.30%

Sep 30, 2025

持股ETF



更新時間: 12月5日週五

機構名稱

佔比

VanEck Biotech ETF

9.71%

ProShares Ultra Nasdaq Biotechnology

8.83%

Invesco Nasdaq Biotechnology ETF

8.76%

iShares Biotechnology ETF

7.43%

Invesco Biotechnology & Genome ETF

5.35%

Natixis Loomis Sayles Focused Growth ETF

4.48%

First Trust NASDAQ Pharmaceuticals ETF

4.23%

First Trust NYSE Arca Biotechnology Index Fund

3.5%

Franklin Genomic Advancements ETF

3.33%

Simplify Health Care ETF

3.25%

VanEck Biotech ETF

佔比9.71%

ProShares Ultra Nasdaq Biotechnology

佔比8.83%

Invesco Nasdaq Biotechnology ETF

佔比8.76%

iShares Biotechnology ETF

佔比7.43%

Invesco Biotechnology & Genome ETF

佔比5.35%

Natixis Loomis Sayles Focused Growth ETF

佔比4.48%

First Trust NASDAQ Pharmaceuticals ETF

佔比4.23%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.5%

Franklin Genomic Advancements ETF

佔比3.33%

Simplify Health Care ETF

佔比3.25%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據